Is clostridium difficile associated with relapse of inflammatory bowel disease? Results from a retrospective and prospective cohort study in the Netherlands

Inflammatory Bowel Diseases

Volumn 19, Issue 10, 2013, Pages 2125-2131

  Masclee, Gwen M C ^a,b   Penders, John ^b,c   Jonkers, Daisy M A E ^a,c   Wolffs, Petra F G ^b,c   Pierik, Marie J ^a,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Medical Microbiology ^*  (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Bacterial pathogen; Clostridium difficile; Exacerbation; Inflammatory bowel disease; Real time polymerase chain reaction

Indexed keywords

ADULT; ARTICLE; CAMPYLOBACTER JEJUNI; CLOSTRIDIUM DIFFICILE; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NONHUMAN; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; RELAPSE; SALMONELLA; SHIGELLA; ULCERATIVE COLITIS; YERSINIA;

ADULT; CHRONIC DISEASE; CLOSTRIDIUM DIFFICILE; COLITIS, ULCERATIVE; CROHN DISEASE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84884553359     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318297d222     Document Type: Article

References (41)

1. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004; 53:1471-1478.
2. Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics. 2006;24:797-814.
3. Bokemeyer B, Hardt J, Huppe D, et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis. 2013;7:355-368.
4. Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16:775-778.
5. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345-351.
6. Meyer AM, Ramzan NN, Loftus EV Jr, et al. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol. 2004;38:772-775.
7. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339-344.
8. Hodges K, Gill R. Infectious diarrhea: cellular and molecular mechanisms. Gut Microbes. 2010;1:4-21.
9. Bartlett JG, Chang TW, Gurwith M, et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298:531-534.
10. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012;55:65-70.
11. Riggs MM, Sethi AK, Zabarsky TF, et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis. 2007;45:992-998.
12. Ott C, Girlich C, Klebl F, et al. Low risk of Clostridium difficile infections in hospitalized patients with inflammatory bowel disease in a German tertiary referral center. Digestion. 2011;84:187-192.
13. Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology. 1981;80:693-696.
14. Bolton RP, Sherriff RJ, Read AE. Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease? Lancet. 1980;1:383-384.
15. Meyers S, Mayer L, Bottone E, et al. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology. 1981;80:697-670.
16. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009;104:1162-1169.
17. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci. 2010;55:415-420.
18. Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect. 2009;15:12-15.
19. Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579-587.
20. Bossuyt P, Verhaegen J, Van Assche G, et al. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis. 2009;3:4-7.
21. Greenfield C, Aguilar Ramirez JR, Pounder RE, et al. Clostridium difficile and inflammatory bowel disease. Gut. 1983;24:713-717.
22. Rolny P, Järnerot G, Möllby R. Occurrence of Clostridium difficile toxin in inflammatory bowel disease. Scand J Gastroenterol. 1983;18:61-64.
23. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103: 1443-1450.
24. Ananthakrishnan AN, McGinley EL, Saeian K, et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976-983.
25. Kariv R, Navaneethan U, Venkatesh PG, et al. Impact of Clostridium difficile infection in patients with ulcerative colitis. J Crohns Colitis. 2011;5:34-40.
26. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205-210.
27. Goodhand JR, Alazawi W, Rampton DS. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 33:428-441.
28. Berg AM, Kelly CP, Farraye FA. Clostridium difficile infection in the inflammatory bowel disease patients. Inflamm Bowel Dis. 2013;19:194-204.
29. Masclee GM, Penders J, Pierik M, et al. Enteropathogenic viruses: triggers for exacerbation in IBD? A prospective cohort study using real-time quantitative polymerase chain reaction. Inflamm Bowel Dis. 2013;19:124-131.
30. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8-15.
31. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530.
32. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786.
33. Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis after ileal pouchanal anastomosis: a pouchitis disease activity index. Mayo Clinic Proc. 1994;69:409-415.
34. Heim A, CE, Harste G, et al. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol. 2003;70:228-239.
35. Belanger SD, Boissinot M, Clairoux N, et al. Rapid detection of Clostridium difficile in feces by real-time PCR. J Clin Microbiol. 2003;41: 730-734.
36. Penders J, Vink C, Driessen C, et al. Quantification of Bifidobacterium spp., Escherichia coli and Clostridium difficile in faecal samples of breastfed and formula-fed infants by real-time PCR. FEMS Microbiol Lett. 2005;243:141-147.
37. Antonelli E, Baldoni M, Giovenali P, et al. Intestinal superinfections in patients with inflammatory bowel diseases. J Crohns Colitis. 2012;6: 154-159.
38. Brown WJ, Hudson MJ, Patrick S, et al. Search for enteric microbial pathogens in patients with ulcerative colitis. Digestion. 1992;53:121-128.
39. van Buul LW, van der Steen JT, Veenhuizen RB, et al. Antibiotic use and resistance in long term care facilities. J Am Med Dir Assoc. 2012;13: 568.e1-e13.
40. Bauer MP, Veenendaal D, Verhoef L, et al. Clinical and microbiological characteristics of community-onset Clostridium difficile infection in the Netherlands. Clin Microbiol Infect. 2009;15:1087-1092.
41. Lyras D, O'Connor JD, Howarth PM. Toxin B is essential for virulence of Clostridium difficile infection. Nature. 2009;458:1176-1179.